---

OHA Algorithm: Which Drug, for Which HbA1c Range

Step 0 - At Diagnosis (Any HbA1c)

---

HbA1c 6.5% - 7.5% (at or near target)

• Metformin - first-line universally (unless contraindicated: eGFR <30, contrast dye, lactic acidosis risk)
• Alternatives if metformin not tolerated:
  • DPP-4 inhibitor (sitagliptin, vildagliptin) - weight neutral
  • GLP-1 RA (semaglutide, liraglutide) - if obesity
  • SGLT-2 inhibitor (empagliflozin, dapagliflozin) - if CVD/CKD

---

HbA1c 7.5% - 9% (above target)

---

HbA1c 9% - 10% (significantly above target)

• Metformin + 2 agents (e.g., GLP-1 RA + SGLT-2i), OR
• If symptomatic hyperglycemia: add basal insulin (glargine/degludec) 10 units at bedtime + continue OHA

---

HbA1c >10% or Symptomatic (polyuria, polydipsia, weight loss)

• Basal insulin (0.1-0.2 units/kg/day) + Metformin
• Consider GLP-1 RA + basal insulin combination (reduces dose requirement)
• Once HbA1c improves, may de-intensify if hypoglycemia occurs

---

Glycemic Targets (ADA/AACE)

---

Key Points

• Re-check HbA1c every 3 months if not at goal; every 6 months if controlled
• SGLT-2i and GLP-1 RA are preferred add-ons when atherosclerotic CVD, heart failure, or CKD is present - independent of glucose lowering
• Sulfonylureas carry hypoglycemia risk; avoid as first add-on in the elderly
• Pioglitazone is contraindicated in heart failure and bladder cancer history
• A1C <6.5%-7% is associated with lowest risk of microvascular complications

---

VIPoma - Complete Overview

Definition & Eponym

• Verner-Morrison syndrome (after the two physicians who first described it in 1958)
• Pancreatic cholera syndrome

---

Epidemiology

• Incidence: approximately 1 in 10 million per year - extremely rare
• Mean age at presentation: 42-51 years
• No clear gender predominance
• Most are sporadic, but a minority arise in the setting of MEN1 (Multiple Endocrine Neoplasia type 1)

---

Pathophysiology

1. VIP binds to receptors on intestinal epithelial cells → stimulates adenylyl cyclase → ↑ cAMP → massive chloride and fluid secretion into the gut lumen (mechanism identical to cholera toxin)
2. Increases smooth-muscle contractility → profuse diarrhea
3. Inhibits gastric acid secretion → achlorhydria
4. Stimulates renin secretion → secondary hyperaldosteronism → additional potassium wasting (compounding hypokalemia beyond just fecal losses)
5. Promotes hepatic glycogenolysis → glucose intolerance/hyperglycemia
6. Vasodilatory effect → cutaneous flushing (minority of patients)
7. Stimulates calcium reabsorption → mild hypercalcemia

---

Clinical Features (WDHA Syndrome)

The diarrhea is secretory in nature - it does NOT abate with fasting and has NO osmotic gap on stool osmolality testing. This is the key feature distinguishing it from osmotic diarrhea.

---

Tumor Characteristics

• 80-90% arise in the pancreas (most commonly body and tail, 70%)
• 10-20% are extrapancreatic: retroperitoneum, chest, intestine, adrenal gland
• Neural crest tumors (neuroblastomas, ganglioneuroblastomas, ganglioneuromas) and pheochromocytomas can also produce VIP and cause VIPoma syndrome
• Usually large, solitary lesions
• High malignancy rate: 50-89% are metastatic at presentation (most commonly to the liver)
• 5-year survival: >90% for localized disease vs ~60% for metastatic disease

---

Diagnosis

Step 1 - Clinical Suspicion

• Large-volume (>1 L/day) secretory diarrhea that persists during fasting
• Associated hypokalemia and achlorhydria

Step 2 - Biochemical Confirmation

• Serum VIP level >200 pg/mL (fasting) - markedly elevated (normal upper limit: 75-190 pg/mL; VIPoma patients may reach 7200 pg/mL)
• Because VIP secretion is episodic, draw samples during active diarrhea, not during remission; repeat measurements may be needed
• Confirm stool volume >0.5-1.0 L/day during a fast
• Note: Mildly elevated VIP can occur in heart failure, renal disease, inflammatory bowel disease, small bowel resection, radiation enteritis - these must be excluded

Step 3 - Rule Out Other Causes of Secretory Diarrhea (Differential Diagnosis)

Step 4 - Tumor Localization

• CT scan (abdomen/pelvis with IV contrast) - first-line imaging; most VIPomas are large and easily seen
• Endoscopic ultrasound (EUS) - most sensitive for small pancreatic tumors
• Somatostatin receptor scintigraphy (SRS) / Octreoscan - best for detecting metastatic disease; most reliable
• MRI - alternative to CT
• DOTATATE PET scan - increasingly used, highly sensitive for NET metastases
• Preoperative localization is critical since 10% of tumors are extrapancreatic (retroperitoneum or chest)

---

Management

A. Immediate Supportive Care (Priority #1)

• Aggressive IV fluid resuscitation (large volumes often required)
• IV potassium replacement (severe hypokalemia needs aggressive correction)
• Correct metabolic acidosis
• Electrolyte monitoring

B. Medical Therapy - Somatostatin Analogues

• Reduce circulating VIP levels
• Eliminate diarrhea in ~50% of patients
• Decrease stool volume in the majority of the remaining patients
• Effect is usually durable but may require dose escalation over time
• Useful both as pre-operative bridge (stabilizing the patient before surgery) and for unresectable/metastatic disease (long-term symptom control)
• Octreotide LAR 20-30 mg IM every 4 weeks is the long-acting formulation used

• High-dose corticosteroids - some benefit but poorly tolerated
• Antimotility agents (loperamide) - inferior to octreotide

C. Surgical Treatment

• Localized disease in the pancreatic tail (most common): Distal pancreatectomy (often curative)
• Extrapancreatic tumors: retroperitoneal or thoracic resection
• Pre-operative stabilization with fluids/electrolytes and octreotide is mandatory before operating
• Even in metastatic disease, cytoreductive surgery (debulking) is recommended to reduce tumor burden and improve symptom control

D. Management of Metastatic Disease

• Hepatic metastases are present in the majority at diagnosis
• Surgical resection of liver metastases (when feasible)
• Hepatic artery embolization or chemoembolization (TACE)
• Radiofrequency ablation (RFA) or other ablative strategies
• Systemic chemotherapy: Streptozotocin + 5-fluorouracil (historical standard); newer options include everolimus, sunitinib
• PRRT (Peptide Receptor Radionuclide Therapy) with 177Lu-DOTATATE for somatostatin receptor-positive tumors
• Interferon-alpha (second-line)

---

VIPoma in MEN1

• VIPomas have been reported in a few patients with MEN1 (Multiple Endocrine Neoplasia type 1)
• MEN1-associated PanNETs are typically multiple
• Surgery is approached cautiously in MEN1 given the high probability of multiple/recurrent tumors
• For symptomatic or growing tumors >2 cm, surgical resection may still be considered

---

Prognosis

---

Key Distinguishing Features from Other Functional PanNETs

---

• Yamada's Textbook of Gastroenterology, 7th ed., pp. 1777-1778, 1795
• Sabiston Textbook of Surgery, 21st ed., pp. 1593-1594
• Mulholland & Greenfield's Surgery, 7th ed., pp. 2752-2755
• Harrison's Principles of Internal Medicine, 22nd ed. (2025)
• Robbins & Cotran Pathologic Basis of Disease
• Fischer's Mastery of Surgery, 8th ed., p. 5142